Cargando…

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients

ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients. BACKGROUND: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duffaud, Florence, Even, Caroline, Ray-Coquard, Isabelle, Bompas, Emmanuelle, Khoa-Huynh, Thanh, Salas, Sebastien, Cassier, Philippe, Dufresne, Armelle, Bonvalot, Sylvie, Ducimetiere, Francoise, Le Cesne, Axel, Blay, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502564/ https://www.ncbi.nlm.nih.gov/pubmed/22950685 http://dx.doi.org/10.1186/2045-3329-2-11

Ejemplares similares

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
por: Boilève, Alice, et al.
Publicado: (2020)

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
por: Cassier, P A, et al.
Publicado: (2010)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal
por: Duffaud, F, et al.
Publicado: (2010)

Prognosis and predictive value of KIT exon 11 deletion in GISTs
por: Bachet, J-B, et al.
Publicado: (2009)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss
por: Feng, Xiaolan, et al.
Publicado: (2022)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
por: Huynh, Thanh-Khoa, et al.
Publicado: (2014)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2012)

Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy
por: Shankar, Sridhar
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
por: Zhuang, Wei, et al.
Publicado: (2018)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology
por: Dufresne, Armelle, et al.
Publicado: (2014)

Erythropoietin, uncertainty principle and cancer related anaemia
por: Clark, Otavio, et al.
Publicado: (2002)

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
por: de Bernardi, Axel, et al.
Publicado: (2022)

Desmoplastic Small Round Cell Tumor: Current Management and Recent Findings
por: Dufresne, Armelle, et al.
Publicado: (2012)

Expanding the molecular spectrum of tenosynovial giant cell tumors
por: Gauduchon, Thibault, et al.
Publicado: (2022)

Imatinib administration in two patients with liver metastases from GIST and severe jaundice
por: De Pas, T, et al.
Publicado: (2003)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2013)

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2014)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sjo97mbtk3a8v60880on3bpfmt